New drug ACR246 enters early human testing for advanced cancers
Disease control
Recruiting now
This early-stage study tests a new drug, ACR246, in about 77 adults with advanced solid tumors that have stopped responding to standard treatments. The main goal is to find a safe dose and check for side effects. Researchers will also measure how the drug moves through the body a…
Phase: PHASE1 • Sponsor: Hangzhou Adcoris Biopharmacy Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC